Table 1. Baseline characteristics of study participants.
| Descriptor | All patients (N = 33*) |
|---|---|
| Age, mean (95% CI), years | 5.42 (3.44–7.40) |
| Age Group, No. (%): Infant (< 1 year) | 14 (42) |
| Child (>1 year) | 19 (58) |
| Female, No. (%) | 15 (45) |
| Race, No. (%): White | 26 (79) |
| Black | 4 (12) |
| Unknown | 3 (9) |
| Body Mass Index, mean (95% CI), kg/m2 | 17.23 (15.76–18.70) |
| Hospital length of stay, median (range), days | 22.10 (5.20–119.50) |
| PICU length of stay, median (range), days | 10.00 (3.3–33.70) |
| Duration of intubation, median (range), days | 7.37 (2.36–22.78) |
| PRISM III score, mean (95% CI) | 14.72 (4.00–30.00) |
| SOFA score day 1, mean (95% CI) | 7.85 (6.51–9.19) |
| SOFA score day 7, mean (95% CI) | 6.61 (5.42–7.79) |
| Neuromuscular blockade, No. (%): Single dose# | 17 (52) |
| Continuous infusion | 10 (30) |
| Cumulative hydrocortisone equivalent dose, median (range), mg/kg | 20.20 (0–1000) |
| Blood glucose level, mean (95% CI), mg/dL | 160.3 (129.8–190.9) |
| Cumulative insulin dose, median (range), IU | 79.01 (0–134.58) |
| Admission diagnosis, No. (%): Airway/respiratory | 11 (33) |
| Central nervous system | 8 (24) |
| Trauma | 5 (15) |
| Infection/sepsis | 3 (9) |
| Hematology/Oncology | 3 (9) |
| Abdominal | 2 (6) |
| Other | 1 (3) |
* One patient was discharged home prior to second assessment and was excluded from analyses.
# In addition to the dose used for intubation